Search

Displaying results 5241 - 5250 of 8974 in total
  1. Drug

    ARX201

    go.drugbank.com/drugs/DB05082
    Investigational

    (PEG) attachment to human growth hormone, by biosynthetic incorporation of a chemically unique amino acid (ahGH). … ARX201 (PEG-ahGH) is a recombinant form of human growth hormone that has been modified using Ambrx’s patented ReCODE™ technology to achieve precise spatial positioning of the site of polyethylene glycol

  2. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of

  3. Drug

    Thiohexam

    go.drugbank.com/drugs/DB14200
    Approved

    Sensitivity to Thiohexam may be identified with a clinical patch test.

  4. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. … Trials of this drug have most likely been discontinued by the manufacturer.

  5. Drug

    Clothiapine

    go.drugbank.com/drugs/DB13256
    Approved

    Clothiapine has been approved in European countries and is an atypical antipsychotic, shown to be useful in some treatment-resistant patients.

  6. Drug

    Cathine

    go.drugbank.com/drugs/DB01486
    ExperimentalIllicit

    It belongs to the phenethylamine and amphetamine chemical classes. In the United States, it is classified as a Schedule IV controlled substance.

    Synonyms: d-Nor-psi-ephedrine
  7. Indication

    Cutaneous Leishmaniasis

    go.drugbank.com/conditions/DBCOND0028439
    Drugs: Miltefosine
    Synonyms: Dry form of cutaneous leishmaniasis (disorder)
  8. Drug

    Adlinacogene civaparvovec

    go.drugbank.com/drugs/DB16788
    Investigational

    [L46711] Developed by Sangamo Therapeutics Inc., it is being investigated for the treatment of hemophilia B.[L46706] … It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX.

  9. Drug

    Nitisinone

    go.drugbank.com/drugs/DB00348
    Approved

    Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria. It is sold under the brand names Orfadin and Harliku.

  10. Drug

    REC-994

    go.drugbank.com/drugs/DB15616
    Investigational

    REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).